These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949 [TBL] [Abstract][Full Text] [Related]
5. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432 [TBL] [Abstract][Full Text] [Related]
6. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035 [TBL] [Abstract][Full Text] [Related]
7. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801 [TBL] [Abstract][Full Text] [Related]
9. Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels. Papaliagkas VT; Anogianakis G; Tsolaki MN; Koliakos G; Kimiskidis VK Dement Geriatr Cogn Disord; 2009; 28(1):30-5. PubMed ID: 19628938 [TBL] [Abstract][Full Text] [Related]
10. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783 [TBL] [Abstract][Full Text] [Related]
17. No correlation between time-linked plasma and CSF Abeta levels. Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299 [TBL] [Abstract][Full Text] [Related]
18. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567 [TBL] [Abstract][Full Text] [Related]
20. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]